LozanoR, NaghaviM, ForemanK. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012; 380: 2095–128.
2.
AliM, GirgisS, HassanA. Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Coron Artery Dis2018; 29: 429–37.
3.
MoriyaJ. Critical roles of inflammation in atherosclerosis. J Cardiol2018. [Epub ahead of print].
4.
RidkerPM, EverettBM, ThurenT. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017; 377: 1119–31.
5.
RidkerPM, MacFadyenJG, EverettBM. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet2018; 391: 319–28.
6.
RidkerPM, HowardCP, WalterV. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation2012; 126: 2739–48.
7.
ChoudhuryRP, BirksJS, ManiV. Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol2016; 68: 1769–80.
8.
RidkerPM, MacFadyenJG, GlynnRJ. Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol2018; 71: 2405–14.
9.
RidkerPM, MacFadyenJG, ThurenT. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet2017; 390: 1833–42.
10.
BacchiegaBC, BacchiegaAB, UsnayoMJ. Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. J Am Heart Assoc2017; 6: e005038.
11.
CarrollMB, HallerC, SmithC. Short-term application of tocilizumab during myocardial infarction (STAT-MI). Rheumatol Int2018; 38: 59–66.
12.
MisraDP, ShenoySN. Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int2017; 37: 151–67.
